Associations - PD-L2 overexpression

BIOMARKER:

PD-L2 overexpression

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

PD-L2 overexpression PD-L2 overexpression	Prostate Cancer Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
PD-L2 overexpression PD-L2 overexpression	Melanoma Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L2 overexpression PD-L2 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PD-L2 overexpression PD-L2 overexpression	Acute Myelogenous Leukemia AML	avelumab Resistant: D – Preclinical avelumab Resistant : D
PD-L2 overexpression PD-L2 overexpression	Colorectal Adenocarcinoma Colorectal Adenocarcinoma	PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + PD-L2 inhibitor Sensitive : D